MicroGenDX
Eric Rees has a diverse work experience in various roles and organizations. Eric is currently working as the Chief Technology Officer at MicroGenDX since October 2020. Prior to that, they worked at Texas Tech University where they held multiple positions including Instructor in the Computer Science Department, Assistant Managing Director, and Research Associate at the High Performance Computing Center. From 2009 to 2016, Eric worked at RTLGenomics as the Director of Bioinformatics, leading the management of projects and providing customer support. Eric also worked as a Bioinformatics Scientist, conducting research in distributed computing techniques and algorithms. Before that, they had roles at Texas Tech University as a Graduate Part Time Instructor, Graduate Teaching Assistant, and Graduate Research Assistant. Early in their career, they also had a research internship at NASA Ames Research Center with Mission Critical Technologies.
Eric Rees earned a Bachelor of Science degree in Computer Science from Angelo State University, where they studied from 2001 to 2005. Following their undergraduate studies, Eric pursued further education and obtained a PhD in Computer Science from Texas Tech University. Eric completed their doctoral program at Texas Tech from 2005 to 2011.
This person is not in any teams
This person is not in any offices
MicroGenDX
MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions. MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.